Selective reduction of cysteine-engineered antibodies
The present invention relates to a process for the selective reduction of cysteine-engineered antibodies comprising reacting an antibody comprising one or more engineered cysteines at positions selected from HC40, HC41,HC42, HC89, HC152, HC153, HC155, HC171, LC40, LC41, LC165, and LC168 with a compound according to formula (I), (II), (III), (IV), (V), (VI) or (VII): (I) (II) (III) (IV) (V) (VI) (VII), and to a process for the preparation of antibody conjugates, including antibody-drug conjugates (ADCs).
1. A process, which comprises reacting an antibody comprising one or more engineered cysteines at positions selected from heavy chain 40, 41, 42 and 89 according to the Kabat numbering system, heavy chain 152, 153, 155, and 171 according to the Eu numbering system, light chain 40 and 41 according to the Kabat numbering system, and light chain 165 and 168 according to the Eu numbering system, with a compound according to formula (I), (II), (III), (IV), (V), (VI) or (VII)
or a salt thereof, to reduce said one or more engineered cysteines.
2. The process according to claim 1 , wherein the antibody comprises one or more engineered cysteines at positions selected from heavy chain 40, 41, 42, 152, and 153 and light chain 40, 41, and 165.
3. The process according to claim 1 , wherein the antibody comprises one or more engineered cysteines at positions selected from heavy chain 41 and 42, and light chain 40 and 41.
4. The process according to claim 1 , wherein the compound according to formula (I), (II), (III), (IV), (V), (VI) or (VII) is present in an amount of at least one molar equivalent per molar amount of engineered cysteine.
5. The process according to claim 1 , wherein the antibody is a monospecific antibody against one of the targets selected from the group consisting of annexin A1, B7H4, CA6, CA9, CA15-3, CA19-9, CA125, CA242, CCR2, CCR5, CD2, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD44, CD47, CD56, CD70, CD74, CD79, CD115, CD123, CD138, CD203c, CD303, CD333, CEA, CEACAM, CLCA-1, CLL-1, c-MET, Cripto, CTLA4, DLL3, EGFL, EGFR, EPCAM, EPh antibodies, such as EphA2 or EPhB3, ETBR, FAP, FcRL5, FGF, FGFR3, FOLR1, GCC, GPNMB, HER2, HMW-MAA, integrin, IGF1R, L6, Lewis A like carbohydrate, Lewis X, Lewis Y, LIV1, mesothelin, MUC1, MUC16, NaPi2b, Nectin-4, PSMA, PTK7, SLC44A4, STEAP-1, 5T4 (or TPBG, trophoblast glycoprotein), TF (tissue factor), TF-Ag, Tag72, TNF, TROP2, VEGF and VLA; or a bispecific antibody against a combination of two targets selected from said group.
6. The process according to claim 1 , further comprising conjugating said reduced engineered cysteine with a therapeutic moiety, a radiopharmaceutical, a fluorescent label or a hydrophilic polymer via a cleavable or non-cleavable linker to form an antibody conjugate.
7. The process according to claim 6 , wherein the therapeutic moiety is a tubulin inhibitor, a ribosome-inactivating protein, a DNA minor groove binding agent, a DNA damaging agent, a DNA alkylating agent, a DNA intercalating agent, a DNA crosslinking agent, an RNA polymerase inhibitor, a DNA cleaving agent or an agent that disrupts protein synthesis or the function of essential cellular proteins.
8. The process according to claim 6 , wherein the therapeutic moiety is a duocarmycin, a CBI dimer, a calicheamicin, a PBD, a PBD dimer, a maytansinoid, a tubulysin, a camptothecin, an amanitin or an auristatin derivative.
9. The process according to claim 6 , wherein said antibody conjugate is according to formula (VIII),
wherein
n is 0-3,
m represents an average DAR of from 1 to 6,
R 1 is selected from
y is 1-16, and
R 2 is selected from
10. The process according to claim 9 , wherein said antibody conjugate is according to formula (IX)
11. The process according to claim 1 , wherein said reaction is carried out in a buffered aqueous solution.
12. The process according to claim 6 , wherein the compound according to formula (I), (II), (III), (IV), (V), (VI) or (VII) is present in an amount of 2 to 16 molar equivalents per engineered cysteine of said antibody.
13. The process according to claim 12 , which further comprises removing any unreacted reducing agent prior to said conjugation reaction.
14. The process according to claim 13 , wherein said removing step does not use ultrafiltration/diafiltration (UF/DF) or tangential flow filtration (TFF).
15. The process according to claim 13 , wherein said removing step uses active carbon filtration.
16. The process according to claim 6 , wherein said reduction reaction is carried out in a buffered aqueous solution.
17. The process according to claim 3 , wherein the antibody comprises one engineered cysteine at heavy chain position 41.
18. The process according to claim 1 , wherein the compound is a compound according to formula (I) or a salt thereof.
19. The process according to claim 1 , wherein the antibody is selected from the group consisting of an anti-CD115 antibody, an anti-CD123 antibody, an anti-c-MET antibody, an anti-Cripto antibody, an anti-FAP antibody, an anti-GPNMB antibody, an anti-HER2 antibody, an anti-integrin antibody, an anti-Lewis Y antibody, an anti-MUC1 antibody, an anti-MUC16 antibody, an anti-PSMA antibody, an anti-5T4 antibody, an anti-TF antibody, an anti-TF-Ag antibody, an anti-Tag72 antibody and an anti-TROP2 antibody.
20. The process according to claim 8 , wherein the therapeutic moiety is a duocarmycin derivative.